Cover Image
市場調查報告書

卵巢癌:開發中產品分析

Ovarian Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229719
出版日期 內容資訊 英文 1887 Pages
訂單完成後即時交付
價格
Back to Top
卵巢癌:開發中產品分析 Ovarian Cancer - Pipeline Review, H2 2016
出版日期: 2016年12月28日 內容資訊: 英文 1887 Pages
簡介

卵巢癌的大多數發生在卵巢的表皮(外薄膜)。卵巢癌的徵兆和症狀,有骨盆的不舒服和疼痛,消化不良,噁心,便秘和排便週期變化,食慾不振,腰痛等。該疾病的原因,與老齡化和血統有很大的關係。

本報告提供卵巢癌治療藥的開發中產品的概要和臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等。

簡介

卵巢癌概要

治療藥的開發

卵巢癌:企業正在開發的治療藥

卵巢癌:大學/機關研究中的治療藥

卵巢癌:開發中產品概況

卵巢癌:企業開發中的產品

卵巢癌:大學/機關研究中的產品

卵巢癌的治療藥的開發企業

卵巢癌:治療藥的評估

藥物簡介

卵巢癌:暫停中的計劃

卵巢癌:開發中止的產品

卵巢癌:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8866IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H2 2016, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 15, 115, 119, 7, 195, 31 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 11, 34 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Ovarian Cancer Overview
  • Therapeutics Development
  • Ovarian Cancer - Therapeutics under Development by Companies
  • Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes
  • Ovarian Cancer - Pipeline Products Glance
  • Ovarian Cancer - Products under Development by Companies
  • Ovarian Cancer - Products under Investigation by Universities/Institutes
  • Ovarian Cancer - Companies Involved in Therapeutics Development
  • Ovarian Cancer - Therapeutics Assessment
  • Drug Profiles
  • Ovarian Cancer - Dormant Projects
  • Ovarian Cancer - Discontinued Products
  • Ovarian Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Ovarian Cancer, H2 2016
  • Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Development by Companies, H2 2016 (Contd..11)
  • Number of Products under Development by Companies, H2 2016 (Contd..12)
  • Number of Products under Development by Companies, H2 2016 (Contd..13)
  • Number of Products under Development by Companies, H2 2016 (Contd..14)
  • Number of Products under Development by Companies, H2 2016 (Contd..15)
  • Number of Products under Development by Companies, H2 2016 (Contd..16)
  • Number of Products under Development by Companies, H2 2016 (Contd..17)
  • Number of Products under Development by Companies, H2 2016 (Contd..18)
  • Number of Products under Development by Companies, H2 2016 (Contd..19)
  • Number of Products under Development by Companies, H2 2016 (Contd..20)
  • Number of Products under Development by Companies, H2 2016 (Contd..21)
  • Number of Products under Development by Companies, H2 2016 (Contd..22)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Development by Companies, H2 2016 (Contd..17)
  • Products under Development by Companies, H2 2016 (Contd..18)
  • Products under Development by Companies, H2 2016 (Contd..19)
  • Products under Development by Companies, H2 2016 (Contd..20)
  • Products under Development by Companies, H2 2016 (Contd..21)
  • Products under Development by Companies, H2 2016 (Contd..22)
  • Products under Development by Companies, H2 2016 (Contd..23)
  • Products under Development by Companies, H2 2016 (Contd..24)
  • Products under Development by Companies, H2 2016 (Contd..25)
  • Products under Development by Companies, H2 2016 (Contd..26)
  • Products under Development by Companies, H2 2016 (Contd..27)
  • Products under Development by Companies, H2 2016 (Contd..28)
  • Products under Development by Companies, H2 2016 (Contd..29)
  • Products under Development by Companies, H2 2016 (Contd..30)
  • Products under Development by Companies, H2 2016 (Contd..31)
  • Products under Development by Companies, H2 2016 (Contd..32)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Ovarian Cancer - Pipeline by 3-V Biosciences Inc, H2 2016
  • Ovarian Cancer - Pipeline by 4SC AG, H2 2016
  • Ovarian Cancer - Pipeline by AB Science SA, H2 2016
  • Ovarian Cancer - Pipeline by AbbVie Inc, H2 2016
  • Ovarian Cancer - Pipeline by AbGenomics International Inc, H2 2016
  • Ovarian Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016
  • Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
  • Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016
  • Ovarian Cancer - Pipeline by Aduro BioTech Inc, H2 2016
  • Ovarian Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2016
  • Ovarian Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016
  • Ovarian Cancer - Pipeline by Advaxis Inc, H2 2016
  • Ovarian Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016
  • Ovarian Cancer - Pipeline by Aeterna Zentaris Inc, H2 2016
  • Ovarian Cancer - Pipeline by Alchemia Ltd, H2 2016
  • Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2016
  • Ovarian Cancer - Pipeline by Almac Discovery Ltd, H2 2016
  • Ovarian Cancer - Pipeline by Alpha Cancer Technologies Inc, H2 2016
  • Ovarian Cancer - Pipeline by Alteogen Inc, H2 2016
  • Ovarian Cancer - Pipeline by Ambrx Inc, H2 2016
  • Ovarian Cancer - Pipeline by Amgen Inc, H2 2016
  • Ovarian Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016
  • Ovarian Cancer - Pipeline by ANP Technologies Inc, H2 2016
  • Ovarian Cancer - Pipeline by AntiCancer Inc, H2 2016
  • Ovarian Cancer - Pipeline by Antoxis Ltd, H2 2016
  • Ovarian Cancer - Pipeline by Apac Biotech Pvt Ltd, H2 2016
  • Ovarian Cancer - Pipeline by Aphios Corp, H2 2016
  • Ovarian Cancer - Pipeline by Aposense Ltd, H2 2016
  • Ovarian Cancer - Pipeline by Aprea AB, H2 2016
  • Ovarian Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016
  • Ovarian Cancer - Pipeline by arGEN-X BV, H2 2016
  • Ovarian Cancer - Pipeline by ARMO Biosciences Inc, H2 2016
  • Ovarian Cancer - Pipeline by Armour Therapeutics Inc, H2 2016
  • Ovarian Cancer - Pipeline by Arno Therapeutics Inc, H2 2016
  • Ovarian Cancer - Pipeline by Arog Pharmaceuticals Inc, H2 2016
  • Ovarian Cancer - Pipeline by ArQule Inc, H2 2016
  • Ovarian Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016
  • Ovarian Cancer - Pipeline by Arvinas Inc, H2 2016
  • Ovarian Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2016
  • Ovarian Cancer - Pipeline by Astellas Pharma Inc, H2 2016
  • Ovarian Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016
  • Ovarian Cancer - Pipeline by AstraZeneca Plc, H2 2016
  • Ovarian Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2016
  • Ovarian Cancer - Pipeline by Athenex Inc, H2 2016
  • Ovarian Cancer - Pipeline by ATLAB Pharma SAS, H2 2016
  • Ovarian Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016
  • Ovarian Cancer - Pipeline by Avipep Pty Ltd, H2 2016
  • Ovarian Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016
  • Ovarian Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016
  • Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H2 2016
  • Ovarian Cancer - Pipeline by Bayer AG, H2 2016
  • Ovarian Cancer - Pipeline by BeiGene Ltd, H2 2016
  • Ovarian Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016
  • Ovarian Cancer - Pipeline by BioCancell Ltd, H2 2016
  • Ovarian Cancer - Pipeline by BioMoti Ltd, H2 2016
  • Ovarian Cancer - Pipeline by Bionomics Ltd, H2 2016
  • Ovarian Cancer - Pipeline by BioNTech AG, H2 2016
  • Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H2 2016
  • Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Ovarian Cancer - Pipeline by Boston Biomedical Inc, H2 2016
  • Ovarian Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Ovarian Cancer - Pipeline by Calithera Biosciences Inc, H2 2016
  • Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2016
  • Ovarian Cancer - Pipeline by Cavion LLC, H2 2016
  • Ovarian Cancer - Pipeline by Cellceutix Corp, H2 2016
  • Ovarian Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016
  • Ovarian Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016
  • Ovarian Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2016
  • Ovarian Cancer - Pipeline by Celon Pharma SA, H2 2016
  • Ovarian Cancer - Pipeline by Celprogen Inc, H2 2016
  • Ovarian Cancer - Pipeline by Celsion Corp, H2 2016
  • Ovarian Cancer - Pipeline by Celyad SA, H2 2016
  • Ovarian Cancer - Pipeline by Ceronco Biosciences, H2 2016
  • Ovarian Cancer - Pipeline by CerRx Inc, H2 2016
  • Ovarian Cancer - Pipeline by Cerulean Pharma Inc, H2 2016
  • Ovarian Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016
  • Ovarian Cancer - Pipeline by Cielo Therapeutics Inc, H2 2016
  • Ovarian Cancer - Pipeline by Clovis Oncology Inc, H2 2016
  • Ovarian Cancer - Pipeline by CohBar Inc, H2 2016
  • Ovarian Cancer - Pipeline by Coherus BioSciences Inc, H2 2016
  • Ovarian Cancer - Pipeline by Commence Bio Inc, H2 2016
  • Ovarian Cancer - Pipeline by Compliment Corp, H2 2016

List of Figures

  • Number of Products under Development for Ovarian Cancer, H2 2016
  • Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top